Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# Ratio Therapeutics 

## Sitemaps

- [XML Sitemap](https://ratiotx.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Blog](https://ratiotx.com/blog/)
- [Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure](https://ratiotx.com/2026/07/31/ratio-therapeutics-closes-70-million-series-c-financing-to-advance-clinical-development-of-targeted-radiotherapeutics-pipeline-and-expand-manufacturing-infrastructure/) - Round brings total capital raised to over $240 Million. BOSTON, July 31, 2026 - Ratio Therapeutics, Inc. (Ratio), a clinical-stage pharmaceutical company developing best-in-class radiopharmaceuticals for cancer treatment, today announced the closing of a $70 million Series C financing. The financing included strong participation from existing investors Duquesne Family Office and Bristol Myers Squibb, along with new
- [Ratio Therapeutics Enters Strategic Actinium-225 Supply Agreement with PanTera to Support Radiopharmaceutical Development Programs](https://ratiotx.com/2026/06/30/ratio-therapeutics-enters-strategic-actinium-225-supply-agreement-with-pantera-to-support-radiopharmaceutical-development-programs/) - Collaboration strengthens Ratio's long-term isotope supply strategy for clinical development and future pipeline growth BOSTON, MA, June 30, 2026 - Ratio Therapeutics Inc. (Ratio), a clinical-stage pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced that it has entered into a strategic supply agreement with PanTera, an innovative producer scaling the supply
- [Ratio Therapeutics and PharmaLogic Expand Manufacturing Collaboration to Support Clinical Development of [Ac-225]RTX-2358](https://ratiotx.com/2026/05/29/ratio-therapeutics-and-pharmalogic-expand-manufacturing-collaboration-to-support-clinical-development-of-ac-225rtx-2358/) - Expanded collaboration adds manufacturing capacity, strengthens redundancy, and supports later-stage development planning for Ratio’s lead FAP-targeted radiotherapeutic candidate BOSTON, May 29, 2026 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced an expanded manufacturing collaboration with PharmaLogic Holdings Corp. (PharmaLogic), a leading contract development and manufacturing
- [Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer](https://ratiotx.com/2026/03/12/ratio-therapeutics-appoints-global-medical-leader-colin-hayward-as-chief-medical-officer/) - BOSTON, March 12, 2026 - Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Colin Hayward, MBBS, FFPM, as the company's Chief Medical Officer. Dr. Hayward brings more than 26 years of global experience in the healthcare industry, including leadership in
- [Ratio Therapeutics has successfully dosed the first cohort in its Phase 1/2 study evaluating a novel FAP-targeted radiopharmaceutical in patients with late-stage aggressive sarcomas](https://ratiotx.com/2025/12/16/ratio-therapeutics-has-successfully-dosed-the-first-cohort-in-its-phase-1-2-study-evaluating-a-novel-fap-targeted-radiopharmaceutical-in-patients-with-late-stage-aggressive-sarcomas/) - BOSTON, MA, December 16, 2025 - Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that dosing of the first cohort has been completed in the ATLAS trial, a Phase 1/2 open-label study evaluating the safety, tolerability, and efficacy of the company’s lead
- [Ratio Therapeutics Announces the Appointment of Marcel Reichen as Chief Strategy Officer](https://ratiotx.com/2025/11/04/ratio-therapeutics-announces-the-appointment-of-marcel-reichen-as-chief-strategy-officer/) - BOSTON, November 4, 2025 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Marcel Reichen, Ph.D., MBA, as the company’s Chief Strategy Officer. Dr. Reichen brings over a decade of international experience in the pharmaceutical and radioligand therapy (RLT) industries,
- [Ratio Therapeutics and TerraPower Isotopes Sign Supply Agreement for Actinium-225 For Targeted Radiotherapeutics](https://ratiotx.com/2025/06/20/ratio-therapeutics-and-terrapower-isotopes-sign-supply-agreement-for-actinium-225-for-targeted-radiotherapeutics/) - BOSTON and BELLEVUE, WA, June 20, 2025 - Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, and TerraPower Isotopes, a subsidiary of TerraPower, a leading nuclear innovation company, today announced they entered into a supply agreement for the medical radioisotope actinium-225 (Ac-225)1. Under the agreement,
- [June 17th, 2025: Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals](https://ratiotx.com/2025/06/17/june-17th-2025-ratio-therapeutics-and-nusano-enter-long-term-multi-isotope-supply-agreement-to-boost-production-of-cancer-radiopharmaceuticals/) - Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeutics Accelerates Ratio’s clinical pipeline with copper-64 for PET imaging and luetium-177 and actinium-225 for targeted therapy Bolsters both companies’ manufacturing and supply chain capabilities in Utah BOSTON and WEST VALLEY CITY, Utah – June 17, 2025 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical
- [June 13, 2025: Ratio Therapeutics Partners with Macrocyclics for Exclusive Manufacturing and Distribution of its Radiopharmaceutical Chelator Platform](https://ratiotx.com/2025/06/13/june-13-2025-ratio-therapeutics-partners-with-macrocyclics-for-exclusive-manufacturing-and-distribution-of-its-radiopharmaceutical-chelator-platform/) - BOSTON, June 13, 2025 /PRNewswire/ — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that it entered into an agreement granting Macrocyclics Inc. (Macrocyclics) exclusive manufacturing and distribution rights to Ratio’s proprietary chelator MacropaTM enabling broad access worldwide. Macropa is a proprietary, best-in-class, bifunctional
- [May 8th, 2025: Ratio Therapeutics to Establish New Radiopharmaceutical Manufacturing Facility](https://ratiotx.com/2025/05/08/ratio-therapeutics-to-establish-new-radiopharmaceutical-manufacturing-facility/) - New facility will be part of Wasatch Group’s Medical Innovation Technology Research Campus, a premier hub for cutting-edge medical manufacturing and collaboration located in Salt Lake City, Utah BOSTON, May 8, 2025 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced that it
- [November 18th, 2024: Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate](https://ratiotx.com/2024/11/18/november-18th-2024-ratio-enters-license-and-collaboration-agreement-with-novartis-for-sstr2-targeting-radiotherapeutic-candidate/) - Ratio to to receive upfront, and potential milestones and tiered royalty payments BOSTON, November 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE:
- [June 20th, 2024: Ratio Therapeutics Announces the Appointment of Former Senator William Cowan to its Board of Directors](https://ratiotx.com/2024/06/20/ratio-therapeutics-announces-the-appointment-of-former-senator-william-cowan-to-its-board-of-directors/) - BOSTON, June 20, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Former U.S. Senator William “Mo” Cowan to its Board of Directors. Senator Cowan brings a wealth of experience in government, law, healthcare, and public policy
- [May 6th, 2024: Ratio Therapeutics Announces the Appointment of Marc Becker as Chief Financial Officer and Chief Operating Officer](https://ratiotx.com/2024/05/06/may-6th-2024-ratio-therapeutics-announces-the-appointment-of-marc-becker-as-chief-financial-officer-and-chief-operating-officer/) - BOSTON, May 6, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Marc Becker as the company’s Chief Financial Officer and Chief Operating Officer. This appointment will reinforce Ratio’s financial and operational leadership by bringing significant experience
- [April 2nd, 2024: Ratio Strengthens its Leadership Team with the Appointments of Bill Cupelo as Chief Business Officer and D. Scott Holbrook to its Board of Directors](https://ratiotx.com/2024/04/02/ratio-strengthens-its-leadership-team-with-the-appointments-of-bill-cupelo-as-chief-business-officer-and-d-scott-holbrook-to-its-board-of-directors/) - BOSTON, April 2, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointments of Bill Cupelo as the company’s Chief Business Officer and D. Scott Holbrook, MS, FSNMMI-TS to its Board of Directors. These strategic additions to Ratio’s leadership
- [March 12th, 2024: Ratio Announces Expansion of Manufacturing Agreement with PharmaLogic for FAP-Targeted Radiopharmaceuticals](https://ratiotx.com/2024/03/12/march-12th-2024-ratio-announces-expansion-of-manufacturing-agreement-with-pharmalogic-for-fap-targeted-radiopharmaceuticals/) - BOSTON, MA and BOCA RATON, FL - March 12th, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced an expanded manufacturing agreement with PharmaLogic, a world-class contract development and manufacturing organization (CDMO) specializing in radiopharmaceutical production and distribution. The collaboration
- [June 10th, 2022: Ratio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of Cancers](https://ratiotx.com/2022/06/10/ratio-therapeutics-raises-20m-in-series-a-financing/) - Company Emerges from Stealth Mode with More Than $20 Million in Seed Financing and Fully Funded Development Alliances with Bayer and Lantheus BOSTON, June 10, 2022 /PRNewswire/ — Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted radiopharmaceuticals for the treatment of cancers. Founded by entrepreneurial scientists Jack Hoppin, Ph.D., and John Babich, Ph.D., Ratio emerges from stealth mode with more
- [July 6th, 2022: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225](https://ratiotx.com/2022/07/06/ratio-therapeutics-cfo-gets-due-diligence-ready/) - Berlin, 6 July 2022. Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225. The agreement covers the development of a validated manufacturing process as well as the GMP-compliant production of clinical investigational
- [September 15th, 2022: Ratio Therapeutics Appoints Jacob Hesterman, Ph.D., as Chief Data Officer](https://ratiotx.com/2022/09/15/325-jack-hoppin-and-john-babich-of-ratio-therapeutics/) - BOSTON, September 15, 2022 – Ratio Therapeutics Inc., a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers, today announced the appointment of Jacob Hesterman, Ph.D., as the company’s Chief Data Officer (CDO). In this newly created role, Dr. Hesterman will build the company’s data management
- [December 6th, 2022: Ratio Therapeutics Appoints Reed Malleck as Chief Financial Officer](https://ratiotx.com/2022/12/06/ratio-to-fine-tune-radioligand-approach-in-cancer-with-trillium-and-macropa-platforms/) - BOSTON, December 6, 2022 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers, today announced the appointment of Reed Malleck as the company’s Chief Financial Officer (CFO). Mr. Malleck comes to Ratio with more than 25 years of finance and
- [February 1st, 2023: Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment](https://ratiotx.com/2023/02/01/fda-guiding-industry-to-optimize-cancer-drug-dosing-in-precision-oncology-era-2/) - Boston-Based Pharmaceutical Company Brings Total Financing to More Than $40 Million since 2022 Launch Dr. Susan K. Whoriskey, Ph.D., to Join the Company’s Board of Directors as Strategic Advisor BOSTON, February 1, 2023 – Ratio Therapeutics Inc., a pharmaceutical company specializing in the development of targeted radiotherapeutics for the treatment of cancer, announces the close of
- [March 13th, 2023: Ratio Therapeutics Appoints Dr. Noel Monks as Head of Biology](https://ratiotx.com/2023/03/13/radiopharmaceuticals-on-their-way-to-becoming-mainstream-cancer-therapies/) - BOSTON, March 13, 2023 /PRNewswire/ — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company specializing in the development of targeted radiotherapeutics for the treatment of cancer, today announced the appointment of Dr. Noel Monks as the company’s Head of Biology. Dr. Monks joins Ratio with over 20 years of experience in drug discovery, development, and translational medicine in the fields of
- [March 28th, 2023: Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck](https://ratiotx.com/2023/03/28/ratio-therapeutics-unveils-new-research-and-development-facility/) - Collaboration to develop a Granzyme B-targeted agent for PET imaging applications in inflammation and cancer indications BOSTON, March 28, 2023 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the monitoring and treatment of cancers, today announced the licensing of a Granzyme B-targeted agent for PET
- [May 9th, 2023: Ratio Therapeutics Announces Opening of New Research and Development Facility](https://ratiotx.com/2023/05/09/the-dawn-of-the-interim-cfo/) - Boston-based fast-growing radiopharmaceutical company opens the doors to its new headquarters and research facility to advance targeted radiotherapies for cancer BOSTON, May 9, 2023 – Ratio Therapeutics Inc., a pharmaceutical company focused on developing innovative radiopharmaceuticals for the treatment of cancer, is pleased to announce the opening of its new 19,000-square-foot headquarters and R&D facility in
- [July 11th, 2023: Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging](https://ratiotx.com/2023/07/11/ratio-tuning-the-pharmacokinetics-of-radiotherapies/) - A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers. BOSTON, July 11th, 2023 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the monitoring and treatment of cancers today announced, in partnership with
- [January 17th, 2024: Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment](https://ratiotx.com/2024/01/17/january-17th-2024-ratio-therapeutics-announces-50m-series-b-financing-to-advance-targeted-radiotherapies-for-cancer-treatment/) - Boston-Based Radiopharmaceutical Company Brings Total Financing to More Than $90Million Since 2021 Launch BOSTON, January 17, 2024 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the treatment and monitoring of cancers, today announces the close of its $50M Series B financing, bringing the

## Pages

- [Homepage](https://ratiotx.com/) - Developing best-in-class radiopharmaceuticals for cancer patients A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers. Innovative Technologies Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack
- [The Team](https://ratiotx.com/the-team/) - Leadership Team Jack Hoppin, Ph.D. Chairman, Chief Executive Officer Konica Minolta Precision Medicine (President), Invicro (Co-Founder), Emit Imaging (Co-Founder, Chairman) John Babich, Ph.D. Director, President, Chief Scientific Officer Weill Cornell Medicine, Molecular Insight Pharmaceuticals (Co-Founder), MGH/HMS, RMH/ICR, NASA, BNL Marc Becker, M.B.A, CPA Chief Financial and Operating Officer KPMG, BankBoston (now Bank of America), Genzyme,
- [Media](https://ratiotx.com/media_draft/) - Media Radiopharmaceutical Manufacturing: Ratio Therapeutics on Why Location and Logistics Matter XTalks | June 1st, 2026 Next-generation radiopharmaceuticals are advancing precision oncology, but their short shelf lives make manufacturing and logistics critical to clinical and commercial success. Read More Raising The Bar in Radiopharmaceutical Manufacturing Pharmaceutical Online | March 12th, 2026 Ratio Therapeutics' Chief Commercial
- [](https://ratiotx.com/publications-2/) - Publications 2026 Initial Clinical Experience with [177Lu]Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and Dosimetry Journal of Nuclear Medicine, 2026 Lisa Glantschnig, Johanna S. Enke, Bradley W. Schuller, Eric J. Fenn, Alexander Dierks, Marianne Patt, Andreas Rinscheid, Robert Seifert, Lena M. Unterrainer, Lars H. Lindner, Dorit Di Gioia, John W. Babich, Alejandro Amor
- [Our Pipeline](https://ratiotx.com/our-pipeline/) - Our Pipeline Ratio Therapeutics Pipeline Page
- [Careers](https://ratiotx.com/careers/) - Join Our Team At Ratio Therapeutics we strive every day to improve and extend the lives of cancer patients without sacrificing their quality of life. We are currently seeking top talent to join our team of experts focused on the development of novel radiotherapeutics to help us achieve our mission. We offer a dynamic and
- [Our Technology](https://ratiotx.com/our-technology/) - About Ratio's Technology Platforms Ratio Therapeutics’ fully integrated proprietary R&D platforms, Trillium™ and Macropa™, harness the tumor-killing power of the alpha emitting radionuclide actinium-225 to selectively destroy cancer cells. Trillium™ Ratio’s Trillium™ technology is a proprietary and innovative platform that incorporates a tunable, structural motif enabling our compounds to reversibly bind to albumin, thereby modulating their pharmacokinetics (PK)
- [News](https://ratiotx.com/news1/) - No results found.
- [News](https://ratiotx.com/news/) - News July 11, 2023: Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers. Read More May 9, 2023: Ratio
- [Contact Us](https://ratiotx.com/contact-us/) - Address: One Design Center Place Suite 19-601 Boston, MA 02210 Telephone: +1 617-371-8898 Email: info@ratiotx.com Drydock Avenue
- [Press Release - Phase I Novel FAP-Targeted Radiopharmaceutical](https://ratiotx.com/press-release-phase-i-novel-fap-targeted-radiopharmaceutical/) - Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers. BOSTON, July 11th, 2023 – Ratio Therapeutics Inc. (Ratio), a
- [Homepage](https://ratiotx.com/40-2/) - Developing best-in-class radiopharmaceuticals for cancer patients A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers. Innovative Technologies Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack
- [Press Release - Ratio Therapeutics Announces Opening of New Research and Development Facility](https://ratiotx.com/press-release-ratio-therapeutics-announces-opening-of-new-research-and-development-facility/) - Ratio Therapeutics Announces Opening of New Research and Development Facility Boston-based fast-growing radiopharmaceutical company opens the doors to its new headquarters and research facility to advance targeted radiotherapies for cancer BOSTON, May 9, 2023 - Ratio Therapeutics Inc., a pharmaceutical company focused on developing innovative radiopharmaceuticals for the treatment of cancer, is pleased to announce
- [PR - Ratio Merck License Agreement](https://ratiotx.com/pr-ratio-merck-license-agreement/) - Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck Collaboration to develop a Granzyme B-targeted agent for PET imaging applications in inflammation and cancer indications BOSTON, March 28, 2023 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the monitoring and
- [Press Release - Ratio Therapeutics Launches](https://ratiotx.com/press-release-ratio-therapeutics-launches/) - June 10, 2022: Ratio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of Cancers Company Emerges from Stealth Mode with More Than $20 Million in Seed Financing and Fully Funded Development Alliances with Bayer and Lantheus BOSTON, June 10, 2022 /PRNewswire/ -- Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted
- [PR - Ratio Therapeutics Series A](https://ratiotx.com/pr-series-a/) - February 1, 2023: Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment Boston-Based Pharmaceutical Company Brings Total Financing to More Than $40 Million since 2022 Launch Dr. Susan K. Whoriskey, Ph.D., to Join the Company’s Board of Directors as Strategic Advisor BOSTON, February 1, 2023 – Ratio Therapeutics Inc., a pharmaceutical company
- [PR - Noel Monks Ratio Therapeutics Head of Biology](https://ratiotx.com/pr-noel-monks-ratio-therapeutics-head-of-biology/) - Ratio Therapeutics Appoints Dr. Noel Monks as Head of Biology BOSTON, March 13, 2023 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company specializing in the development of targeted radiotherapeutics for the treatment of cancer, today announced the appointment of Dr. Noel Monks as the company's Head of Biology. Dr. Monks joins Ratio with over 20 years of experience
- [PR - Reed Malleck Ratio Therapeutics Chief Financial Officer](https://ratiotx.com/pr-reed-malleck-ratio-therapeutics-chief-financial-officer/) - December 6, 2022: Ratio Therapeutics Appoints Reed Malleck as Chief Financial Officer BOSTON, December 6, 2022 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers, today announced the appointment of Reed Malleck as the company’s Chief Financial Officer (CFO).
- [PR - Jacob Hesterman Ratio Therapeutics Chief Data Officer](https://ratiotx.com/pr-jacob-hesterman-ratio-therapeutics-chief-data-officer/) - September 15, 2022: Ratio Therapeutics Appoints Jacob Hesterman, Ph.D., as Chief Data Officer BOSTON, September 15, 2022 – Ratio Therapeutics Inc., a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers, today announced the appointment of Jacob Hesterman, Ph.D., as the company’s Chief Data Officer (CDO).
- [PR - E & Z Ratio Joint Development](https://ratiotx.com/pr-e-z-ratio-joint-development/) - July 6, 2022: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225 Berlin, 6 July 2022. Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225.

## Categories

- [Press Release](https://ratiotx.com/category/uncategorized/)